Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete
MSU is ahead of schedule and continues testing program Jackson Center, PA May 23, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of Traumatic Brain Injury (TBI) by directly targeting the associated antigens in cerebrospinal ...
Halberd Pre-Clinical Test Protocol Approved
Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month End Jackson Center, PA May 9, 2023 – Halberd Corporation (OTC-PINK: "HALB”) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering will begin as early as next week. Medical literature indicates that a pathophysiologic connection exists between various excess neurotransmitters and ...
Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process Jackson Center, PA May 2, 2023 – Halberd Corporation (OTC-PINK: "HALB”) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of this study by Halberd and Mississippi State University is to discover the effectiveness of the nasal spray against multiple antigens, ...
Halberd Corporation 1Q23 CEO Letter
Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application of this patent protected technology, successfully eradicated each of these bacteria and fungi at the end of March, reported the ...
$HALB CEO, CTO and #YSU’s Dr. Sturrus Discuss CDC, Research Discoveries etc., on “The Street Reports Podcasts” Listen Now!
Jackson Center, PA, April 20, 2023 – Halberd Corporation’s (OTC-PINK: "HALB") President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on “The Street Reports” to discuss the company’s latest research discoveries and progress on eradicating CDC (Centers for Disease Control and Prevention) provided antibiotic resistant bacteria and deadly fungi. Listen here: https://thestreetreports.com/halbs-ceo-cto-and-ysus-dr-sturrus-discuss-cdc-research-discoveries-etc-on-the-street-reports-podcasts-listen-now/ Dr. W. Gregg Sturrus, Chair of ...
ICYMI: Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances
Jackson Center, PA, April 17, 2023 – Halberd Corporation’s (OTC PINK:HALB) successful patent protected research being conducted at Youngstown State University (YSU) on antibiotic resistant bacteria and deadly Candida auris was recently featured in a news segment on Youngstown, OH CBS News affiliate television station, WKBN. Professors and student scholar lab assistants are conducting this intricate research on samples provided by the CDC (Centers for Disease Control and Prevention). Dr. Cooper, Professor, Department of Chemical ...